Table 4.
Subgroup analyses. Association of the analyzed SNPs and the 3-year recurrence probability according to tumor location and gender.
| Polymorphism | N | Median TTR (95%CI) | 3-year recurrence probability ± SE* | HR (95%CI)† Univariate | P† value | HR (95%CI)† Multivariate | P† value |
|---|---|---|---|---|---|---|---|
| LEFT-SIDED TUMORS | |||||||
| NFKBrs28362491 | 0.34 | 0.40 | |||||
| ATTG/ATTG | 30 | 1.8 (1.4, 10.7+) | 0.52±0.10 | 1 (Reference) | 1 (Reference) | ||
| -/ATTG | 35 | 6.6 (2.4, 9.0+) | 0.34±0.09 | 0.59 (0.28, 1.26) | 0.60 (0.26, 1.35) | ||
| -/- | 30 | 5.2 (3.2, 16.8+) | 0.25±0.08 | 0.65 (0.30, 1.45) | 0.64 (0.28, 1.46) | ||
| Leptinrs7799039 | 0.57 | 0.20 | |||||
| A/A | 28 | 3.5 (1.5, 7.1) | 0.38±0.10 | 1 (Reference) | 1 (Reference) | ||
| A/G | 42 | 16.8+ (2.7, 16.8+) | 0.35±0.09 | 0.68 (0.32, 1.45) | 0.53 (0.23, 1.25) | ||
| G/G | 21 | 6.6 (1.6, 8.0+) | 0.37±0.11 | 0.73 (0.30, 1.73) | 0.41 (0.14, 1.21) | ||
| CD36rs3211882 | 0.47 | 0.42 | |||||
| TGT/TGT | 34 | 7.1 (2.3, 10.7+) | 0.33±0.09 | 1 (Reference) | 1 (Reference) | ||
| -/TGT | 39 | 4.9 (1.5, 16.8+) | 0.46±0.09 | 1.46 (0.71, 3.00) | 1.53 (0.73, 3.19) | ||
| -/- | 21 | 6.7+ (1.5, 6.7+) | 0.26±0.10 | 0.96 (0.36, 2.57) | 0.94 (0.34, 2.58) | ||
| DRG1rs5749272 | 0.53 | 0.75 | |||||
| T/T | 33 | 7.1 (1.8, 9.0+) | 0.40±0.10 | 1 (Reference) | 1 (Reference) | ||
| T/C | 35 | 7.2+ (3.5, 7.2+) | 0.29±0.08 | 0.80 (0.36, 1.75) | 0.75 (0.33, 1.69) | ||
| C/C | 26 | 5.2 (1.4, 16.8+) | 0.47±0.11 | 1.25 (0.57, 2.75) | 0.97 (0.42, 2.26) | ||
| NGALrs12006030 | 0.21 | 0.51 | |||||
| C/C | 64 | 7.1 (3.5, 16.8+) | 0.32±0.07 | 1 (Reference) | 1 (Reference) | ||
| C/G | 33 | 4.9 (1.6, 7.9+) | 0.44±0.09 | 1.51 (0.79, 2.89) | 1.26 (0.63, 2.53) | ||
| PPARrs1801282 | 0.26 | 0.085 | |||||
| C/C | 78 | 6.6 (3.5, 10.7+) | 0.33±0.06 | 1 (Reference) | 1 (Reference) | ||
| C/G | 19 | 2.7 (1.5, 16.8+) | 0.52±0.12 | 1.51 (0.73, 3.10) | 2.05 (0.91, 4.65) | ||
| PPARrs3856806 | 0.89 | 0.20 | |||||
| C/C | 76 | 5.7 (3.2, 10.7+) | 0.36±0.06 | 1 (Reference) | 1 (Reference) | ||
| C/T, T/T‡ | 21 | 4.0 (1.5, 16.8+) | 0.40±0.12 | 1.05 (0.50, 2.22) | 1.84 (0.73, 4.64) | ||
| REGIArs10165462 | 0.18 | 0.20 | |||||
| T/T | 34 | 3.5 (1.8, 7.1) | 0.42±0.10 | 1 (Reference) | 1 (Reference) | ||
| T/C | 52 | 16.8+ (4.0, 16.8+) | 0.31±0.07 | 0.60 (0.30, 1.18) | 0.64 (0.31, 1.32) | ||
| C/C | 10 | 1.6 (0.5, 6.3+) | 0.58±0.21 | 1.28 (0.42, 3.93) | 1.76 (0.50, 6.20) | ||
| DSCR1rs6517239 | 0.018 | 0.040 | |||||
| A/A | 73 | 4.0 (1.8, 16.8+) | 0.44±0.06 | 1 (Reference) | 1 (Reference) | ||
| A/G,G/G‡ | 24 | 10.7+ (5.2, 10.7+) | 0.11±0.08 | 0.34 (0.13, 0.88) | 0.36 (0.14, 0.96) | ||
| FEMALE POPULATION | |||||||
| NFKBrs28362491 | 0.36 | 0.48 | |||||
| ATTG/ATTG | 27 | 9.4 (1.5, 9.4) | 0.39±0.10 | 1 (Reference) | 1 (Reference) | ||
| -/ATTG | 40 | 12.2+ (4.9, 12.2+) | 0.24±0.07 | 0.61 (0.27, 1.39) | 0.67 (0.29, 1.57) | ||
| -/- | 22 | 5.4 (1.4, 16.8+) | 0.38±0.11 | 1.04 (0.44, 2.45) | 1.13 (0.46, 2.78) | ||
| Leptinrs7799039 | 0.24 | 0.13 | |||||
| A/A | 23 | 4.9 (1.5, 7.7+) | 0.37±0.10 | 1 (Reference) | 1 (Reference) | ||
| A/G | 45 | 5.9 (2.4, 16.8+) | 0.40±0.08 | 1.01 (0.46, 2.21) | 0.88 (0.38, 2.04) | ||
| G/G | 22 | 12.2+ (4.8, 12.2+) | 0.15±0.08 | 0.49 (0.17, 1.37) | 0.35 (0.11, 1.06) | ||
| CD36rs3211882 | 0.40 | 0.71 | |||||
| TGT/TGT | 26 | 5.7 (1.8, 7.7+) | 0.37±0.11 | 1 (Reference) | 1 (Reference) | ||
| -/TGT | 51 | 16.8+ (4.8, 16.8+) | 0.30±0.07 | 0.74 (0.33, 1.68) | 1.01 (0.43, 2.40) | ||
| -/- | 10 | 5.9 (0.1, 9.4) | 0.31±0.15 | 1.36 (0.48, 3.89) | 1.51 (0.49, 4.66) | ||
| DRG1rs5749272 | 0.59 | 0.42 | |||||
| T/T | 30 | 5.9 (2.1, 9.0+) | 0.34±0.09 | 1 (Reference) | 1 (Reference) | ||
| T/C | 35 | 10.9+ (4.8, 10.9+) | 0.26±0.08 | 0.75 (0.33, 1.74) | 0.62 (0.25, 1.50) | ||
| C/C | 21 | 16.8+ (1.4, 16.8+) | 0.48±0.12 | 1.19 (0.50, 2.84) | 1.09 (0.43, 2.75) | ||
| NGALrs12006030 | 0.96 | 0.54 | |||||
| C/C | 59 | 9.4 (2.8, 16.8+) | 0.36±0.07 | 1 (Reference) | 1 (Reference) | ||
| C/G | 35 | 5.9 (4.8, 10.9+) | 0.26±0.08 | 0.98 (0.49, 1.97) | 1.27 (0.60, 2.69) | ||
| PPARrs1801282 | 0.022 | 0.11 | |||||
| C/C | 77 | 9.4 (5.4, 10.9+) | 0.27±0.05 | 1 (Reference) | 1 (Reference) | ||
| C/G | 17 | 2.4 (0.6, 16.8+) | 0.64±0.13 | 2.29 (1.09, 4.82) | 1.94 (0.87, 4.34) | ||
| PPARrs3856806 | 0.85 | 0.99 | |||||
| C/C | 75 | 5.9 (4.9, 10.9+) | 0.30±0.06 | 1 (Reference) | 1 (Reference) | ||
| C/T, T/T‡ | 20 | 16.8+ (1.1, 16.8+) | 0.43±0.12 | 1.08 (0.49, 2.39) | 1.00 (0.44, 2.28) | ||
| REGIArs10165462 | 0.64 | 0.82 | |||||
| T/T | 34 | 5.9 (1.8, 12.2+) | 0.35±0.09 | 1 (Reference) | 1 (Reference) | ||
| T/C | 50 | 16.8+ (4.8, 16.8+) | 0.30±0.07 | 0.76 (0.38, 1.55) | 0.88 (0.39, 2.00) | ||
| C/C | 8 | 2.8 (0.5, 4.9+) | 0.67±0.25 | 1.23 (0.35, 4.35) | 1.34 (0.36, 5.01) | ||
| DSCR1rs6517239 | 0.079 | 0.053 | |||||
| A/A | 71 | 5.4 (2.8, 16.8+) | 0.39±0.06 | 1 (Reference) | 1 (Reference) | ||
| A/G,G/G‡ | 23 | 9.4 (5.7, 10.3+) | 0.16±0.09 | 0.44 (0.17, 1.13) | 0.37 (0.14, 1.01) | ||
*
Greenwood SE.
+
Estimates were not reached.
†
Based on log-rank test in the univariate analysis and based on Wald test within multivariate Cox proportional hazards model adjusting for stage and type of adjuvant therapy and stratified by race.
‡
In the dominant model.